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Figure 1. Echocardiographic screening for left ventricular hypertrophy-low longitudinal strain phenotype in elderly patients with preserved or mid-range
ejection fraction. BMI = body mass index; GLS = global longitudinal strain; HF = heart failure; LVEF = left ventricular ejection fraction; MACE = major
adverse cardiovascular events; PWT = posterior wall thickness; RAP = right atrial pressure; RV = right ventricle.

associated with MACE: ACC/AHA
stage C heart failure with odds ratio
(OR) of 3.9 (1.2 to 12.6), right atrial
pressure with OR of 1.2 (1.0 to 1.4),
body mass index with OR of 1.1 (1.0 to
1.2), and right ventricular S’ velocity
with OR of 0.81 (0.68 to 0.98).
This is a single center, real world
echocardiographic screening study with
obvious limitations. Although only one
third of patients underwent further evaluation for cardiac amyloidosis based on
treating team decision, the overall prevalence of cardiac amyloidosis in the
study was high. This highlights the
need for practitioner education in best
practices in recognizing and diagnosing
cardiac amyloidosis.2
In conclusion, echocardiographic
screening for left ventricular hypertrophy-low longitudinal strain phenotype in
elderly patients with preserved or midrange ejection fraction identified a cohort
with a high risk of short-term major cardiovascular events. Despite incomplete
screening, this cohort carried a high
prevalence of cardiac amyloidosis.
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Modifiable Risk Factor
Burden Among 3
Different Age Groups
with Heart Failure
Up to 1 in 5 individuals may develop
heart failure (HF) during their lifetimes.1
Although most individuals who are diagnosed with HF are older adults, an
increasing proportion of younger patients
are being diagnosed in recent years.2
These adverse patterns may be a reflection of rising cardiometabolic health burden and obesity in the US and
worldwide.3 Few data exist regarding
outcomes of HF in young adults, largely
due to limited longitudinal follow-up
data. Consequently, we aimed to describe
the long-term mortality of young patients
diagnosed with HF and assess the relative
prognostic value of common comorbidities across age groups.
The National Health and Nutrition
Examination Survey (NHANES) is a
stratified, multistage probability sample
representative of the civilian non-institutionalized US population, described
in detail elsewhere.4 We analyzed data
of participants aged ≥18 years with
self-reported HF enrolled in 6 cycles of
NHANES from January 1, 1999, to
December 31, 2010. These data were
linked with National Death Index data
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provided by the Centers for Disease
Control and Prevention to obtain data
regarding long-term mortality.5 We
summarized baseline characteristics of
adults with HF by age group (younger:
18-54 years, middle-aged: 55-65 years
and older: >65 years) at study entry.
The primary outcome of interest was
all-cause mortality in follow-up. We
used multivariable Cox proportional
hazards models to examine the association between traditional risk factors
(age, gender, presence of hypertension,
diabetes, obesity, smoking status, and
estimated glomerular filtration rate) and
mortality. We performed age-pooled
analyses to examine multiplicative
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interaction terms between age as a linear and categorical variable with each
risk factor. We then used age-stratified
Cox proportional hazards models to
evaluate age-specific associations of
each risk factor with mortality. We further compared the accuracy of these traditional risk factors in predicting
mortality in each age group using
Harrel’s C-statistic. The proportionality
assumption was met for all models
using Schoenfeld residuals. We considered a two-sided p-value below 0.05 to
be statistically significant.
Overall, 1,071 individuals with HF
were followed for 6.7§4.3 years. Younger patients with HF were more often

Black, had better kidney function, and
had higher rates of diabetes, obesity,
and smoking than middle-age and older
adults (Table 1). The median (IQR) age
at death was 55 (50-60) years for young,
69 (65-71) years for middle-aged, and
83 (79-86) years for older adults. Age
modified the association of obesity and
diabetes on subsequent risk of mortality
such that diabetes was associated with
higher mortality risk in younger
(adjusted hazard ratio [HR] 2.11; 95%
confidence interval [CI]: 1.04-4.31) and
middle-aged adults (adjusted HR 2.18;
95% CI: 1.34-3.57) as compared with
older adults (adjusted HR 1.27; 95%
CI: 1.04-1.55); P-interaction<0.05.

Table 1
Baseline characteristics and risk associations with mortality among young, middle-aged, and older adults with heart failure
Ages (Years)
Baseline characteristics
Age, median (IQR) (Years)
Men
Non-Hispanic White
Non-Hispanic Black
Mexican American
Other
Other Hispanic
Estimated glomerular filtration
rate (ml/min/1.73m2)
Hypertension
Diabetes Mellitus
Hemoglobin (mg/dl)
Total leukocyte count (cells/mm3)
Dyslipidemia
Smoker
Previous Stroke
Coronary Artery Disease
Obesity
Heart Rate (bpm)
Body Mass Index (kg/m2)
Serum Creatinine (mg/dl)
Glycosylated Hemoglobin (%)
Age Diagnosed with Heart Failure
Died
Time to Death (years)
Prognostic Associations with Mortality
Presented as Hazard Ratios
(95% Confidence Intervals)
Age (per increase in 1 year)
Women
Hypertension
Diabetes Mellitus
Smoker
Obesity
Estimated glomerular filtration rate
(per increase by 1 ml/min/1.73m2)
Harrell’s C-statistic for model

18-54 (n=154)

55-65 (n=190)

>65 (n=727)

p-value

48 (42, 51)
84 (54.5%)
61 (39.6%)
61 (39.6%)
18 (11.7%)
6 (3.9%)
8 (5.2%)
97.1 (78.5,119.7)

61 (59, 63)
116 (61.1%)
70 (36.8%)
66 (34.7%)
35 (18.4%)
5 (2.6%)
14 (7.4%)
84.2(67.8,99.6)

78 (72, 81)
386 (53.1%)
495 (68.1%)
106 (14.6%)
77 (10.6%)
16 (2.2%)
33 (4.5%)
63.6(47.5,81.2)

<0.01
0.15
<0.01

118 (80.8%)
51 (35.4%)
14.1 (13.1, 15.2)
7.5 (6, 9.1)
101 (66.4%)
103 (66.9%)
22 (14.3%)
24 (15.6%)
70 (54.7%)
72 (62, 84)
30.2 (26.1, 38.8)
.85 (.7, 1.02)
5.5 (5.2, 6)
41 (28, 47)
48 (31.2%)
8.58(5.66, 12.16)
Younger: 18-54 years
(n=154)

159 (85.0%)
100 (55.9%)
14.1 (12.9, 15.1)
7.3 (5.9, 9.2)
143 (76.1%)
135 (71.1%)
32 (16.9%)
42 (22.1%)
86 (55.5%)
70 (62, 82)
31.7(26.6,38.8)
.92 (.8, 1.1)
6.1 (5.6, 7.1)
54 (50, 58)
89 (46.8%)
7.58(5.42, 10.13)
Middle-aged: 55-65 years
(n=190)

580 (84.3%)
299 (47.7%)
13.5 (12.4, 14.7)
7.2 (5.9, 8.6)
458 (65.1%)
400 (55.2%)
170 (23.5%)
114 (15.7%)
286 (46.1%)
70 (62, 78)
28.3(25.2,32.4)
1.11 (.9, 1.49)
5.8 (5.5, 6.5)
69 (61, 77)
530 (72.9%)
5.5 (2.42, 8.42)
Older: >65 years
(n=727)

0.53
<0.01
<0.01
0.57
0.018
<0.01
0.012
0.100
0.040
0.57
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
Overall Cohort

1.01 (0.95 - 1.07)
0.94 (0.48 - 1.84)
0.87(0.37- 2.01)
2.11 (1.04 - 4.31)
2.04 (0.93- 4.47)
2.07 (1.02 - 4.22)
0.98(0.97 - 0.99)

1.07 (0.97 - 1.20)
1.42 (0.89 - 2.28)
1.32 (0.68 - 2.56)
2.18 (1.34 - 3.57)
0.94 (0.56 - 1.59)
0.61 (0.37 - 1.01)
0.99(0.98 - 1.01)

1.09 (1.07 - 1.11)
0.78 (0.63 - 0.96)
0.99 (0.78 - 1.27)
1.27 (1.04 - 1.55)
1.10 (0.90 - 1.34)
1.03 (0.85 - 1.26)
0.99 (0.98 - 0.99)

1.05 (1.04 - 1.06)
0.88 (0.74 − 1.05)
0.99 (0.81 - 1.23)
1.29 (1.09 − 1.54)
1.14(0.72 − 1.81)
1.00 (0.84 - 1.19)
0.99(0.989 - 0.99)

0.71(0.63 - 0.77)

0.67 (0.61 - 0.73)

0.66 (0.63 - 0.69)

0.69(0.67 - 0.71)

<0.01

Data are presented as count (percentage) and median (interquartile range), as appropriate. Models were adjusted for age, gender, history of smoking, presence of diabetes, hypertension, obesity, and estimated glomerular filtration rate.
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Figure 1. Prognostic associations of risk factors with mortality among younger, middle-aged, and older
adults with heart failure. Age significantly modified the association of obesity and diabetes on subsequent risk of mortality (p-interaction<0.05 for both).

Similarly, obesity was associated with
higher risk of mortality in younger
(adjusted HR 2.07; 95% CI: 1.02-4.22)
compared with middle-aged (adjusted
HR 0.61; 95% CI: 0.37- 1.01) and older
adults (adjusted HR 1.03; 95% CI: 0.851.26); p-interaction<0.05; Figure 1. All
other risk factors showed similar prognostic associations with mortality across
the age ranges. Age as a continuous
function did not modify the association
of risk factors with long-term mortality.
Predictive accuracy of multivariable
models declined with increasing age,
with a Harrel’s C- statistic (95% CI) of
0.71(0.63-0.77) in young, 0.67 (0.61 0.73) in middle-aged, and 0.66 (0.630.69) in older adults.
In this longitudinal analysis of adults
in NHANES, we found cardiometabolic
risk factors, including obesity and diabetes, appear more closely linked with mortality in younger adults with HF
compared with older age groups. Furthermore, models including these established, modifiable risk factors were more
accurate and discriminative of subsequent mortality in younger individuals.
In recent years, the incidence of HF
and case mortality rates have remained
large stable in older adults.6 However,
prevalence of HF has consistently been
rising, potentially due to the increase in
the overall population and expansion in
the burden of cardiometabolic risk factors in younger adults.7 Our study highlights that core risk factors, including
ones that are modifiable, discriminate
most deaths among young patients with
HF and represent a key opportunity for

early intervention. Our data are consistent with previous studies that have
shown higher population attributable
risk for traditional risk factors among
young individuals for the development
of HF.3 This study extends these findings and points toward higher predictive ability of these risk factors for
mortality in young patients with HF,
and may inform population-level targeted efforts to slow disease progression and prevent premature mortality at
an earlier time-point.
Our study has certain limitations. As
an administrative and self-reported
dataset, NHANES is susceptible to miscoding and responder bias. Cause-specific deaths were not available for
analysis. Further, to allow for longitudinal follow-up, the baseline cohort was
enrolled in 1999-2010, and standard of
care has evolved since then. Lastly,
data regarding background therapy and
ejection fraction were not available
(Figure 1).
Cardiometabolic risk factors are
more common, carry greater prognostic
association, and when combined with
other traditional risk factors, more
accurately forecast future mortality in
younger adults compared with middleaged or older adults with HF.
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